Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Stopped Merus terminated the study early due to changes in organizational priorities.

Conditions

• NSCLC Harboring NRG1 Fusion
• Metastatic Castration-resistant Prostate Cancer

Interventions

• DRUG: Afatinib Oral Tablet
• DRUG: Enzalutamide Pill
• DRUG: Abiraterone acetate tablets
• BIOLOGICAL: MCLA-128

Sponsor

Partner Therapeutics, Inc.